Omicron Surge: Identify & Access the Only Federally Authorized Outpatient Therapeutics with Locator

COVID-19, Therapeutics, Omicron, SARS-CoV-2, Antiviral, Monoclonal Antibody

Recently, TrialSite reported on early outpatient therapeutics with potential and reminded readers that the only federally authorized outpatient therapeutics (in the United States) that remain significantly efficacious against the Omicron variant of concern are Paxlovid and Sotrovimab. However, both are extremely constrained. Therefore, their use is being restricted to only high-risk patients, but the timing of administration is critical for better outcomes. Of course, with record numbers of SARS-CoV-2 cases in America, this is an unfortunate situation. We're hearing reports of patients' primary care providers being unable to locate available treatments for high-risk patients.

Thanks to a TrialSite team member, we share two great tools to help locate various therapeutics i.e., Paxlovid, Molnupiravir, and Evusheld. To be clear, Evusheld is only for pre-exposure prophylaxis in high-risk individuals. It does retain some of its antibody neutralization activity against the Omicron variant. If you are seeking access to these therapeutics, the following two resources can be used to locate these very difficult-to-find therapies. The first resource covers pharmac...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee